172 related articles for article (PubMed ID: 21706866)
1. [Towards better understanding of hematolymphoid malignancies--based on the WHO-2008 classification: summary].
Tohyama K
Rinsho Byori; 2011 May; 59(5):502-3. PubMed ID: 21706866
[TBL] [Abstract][Full Text] [Related]
2. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
Anastasi J
Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
[TBL] [Abstract][Full Text] [Related]
3. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
4. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
5. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
6. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
7. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD
Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes].
Harada H; Harada Y; Kimura A
Nihon Rinsho; 2009 Oct; 67(10):1901-5. PubMed ID: 19860187
[TBL] [Abstract][Full Text] [Related]
9. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report.
Jaffe ES; Harris NL; Diebold J; Muller-Hermelink HK
Am J Clin Pathol; 1999 Jan; 111(1 Suppl 1):S8-12. PubMed ID: 9894466
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of molecular haematology: an overview.
Bain BJ
J Assoc Physicians India; 2007 Jul; 55():503-6. PubMed ID: 17907501
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Agarwal MB
J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis of myeloid hematologic malignancies: contributions of the 2001 World Health Organization (WHO) classification].
Leymarie V; Galoisy AC; Falkenrodt A; Lessard M
Ann Biol Clin (Paris); 2004; 62(5):513-20. PubMed ID: 15355801
[TBL] [Abstract][Full Text] [Related]
13. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms.
Loghavi S; Kanagal-Shamanna R; Khoury JD; Medeiros LJ; Naresh KN; Nejati R; Patnaik MM;
Mod Pathol; 2024 Feb; 37(2):100397. PubMed ID: 38043791
[TBL] [Abstract][Full Text] [Related]
14. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
[TBL] [Abstract][Full Text] [Related]
15. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours.
Brown NA; Elenitoba-Johnson KS
Head Neck Pathol; 2017 Mar; 11(1):96-109. PubMed ID: 28247223
[TBL] [Abstract][Full Text] [Related]
16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
[TBL] [Abstract][Full Text] [Related]
18. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
19. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL; Pardanani A; Tefferi A; Gilliland DG
Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
[TBL] [Abstract][Full Text] [Related]
20. The WHO classification of the myelodysplastic syndromes.
Bain B
Exp Oncol; 2004 Sep; 26(3):166-9. PubMed ID: 15494682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
